Circulating Tumor DNA and its Use in Colorectal Cancer Treatment Decision-Making

Data from the phase 1/2 KRYSTAL-1 trial may support adagrasib plus cetuximab as a new standard in previously treated metastatic KRAS G12C–mutated CRC.

New studies and treatment options prove to be effective in treating metastatic CRC, notes Joleen Hubbard, MD.

If possible, targeting the BER pathway for drug sensitivities may increase therapeutic options for managing solid cancers, wrote Channing Paller, MD.

Personalized therapy tailored for mutation status is something to expect in the coming years for colorectal cancer treatment, notes Tanios S. Bekaii-Saab, MD.

Gut microbiome signatures may lead the way for more accurate treatments and diagnoses for patients with colorectal cancer.

Investigators will assess A2B530 as a treatment for patients with germline heterozygous HLA-A*02–positive colorectal cancer expressing carcinoembryonic antigen in the phase 1/2 EVEREST-1 trial.